TOAST INC CLASS A (TOST)
Sector: Financials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Financials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for TOST
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| TOST | Director | 69 | [] | ["Compensation Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Patrick has been a member of our Board since February 2021. Mr. Patrick is a Senior Partner of The Vistria Group, a private impact investment firm, having served as a Senior Advisor to the firm from January 2024 to November 2024. Between February 2022 and June 2025, Mr. Patrick served as a professor of the practice of public leadership at the Harvard Kennedy School, where he also served as co-director of the Center for Public Leadership from 2022 until 2024. From March 2021 to December 2023, Mr. Patrick was a Senior Advisor at Bain Capital LLC, where he previously founded and, from April 2015 to December 2019, served as Managing Partner of the Double Impact Fund, an investment fund focused on delivering competitive financial returns and positive social impact. Previously, from January 2007 to January 2015, Mr. Patrick served as Governor of the Commonwealth of Massachusetts. Mr. Patrick has served on the boards of directors of Twilio Inc., a cloud communications developer platform, since January 2021. He previously served on the board of directors of American Well Corp., a telemedicine technology company, from June 2015 to December 2019, and from April 2020 to June 2024 Cerevel Therapeutics Holdings, Inc., a biopharmaceutical company focused on neuroscience, from January 2021 until its acquisition by AbbVie Inc. in July 2024 Environmental Impact Acquisition Corp., a special purpose acquisition company focused on sustainability companies, from January 2021 to February 2022; and Global Blood Therapeutics, Inc., a biotech company focused on therapies to address sickle cell disease, from April 2015 to November 2019, and from May 2020 until its acquisition by Pfizer Inc. in October 2022. In addition, Mr. Patrick serves as a member of several charitable boards. Mr. Patrick holds a B.A. in English and American Literature from Harvard College and a J.D. from Harvard Law School. Mr. Patrick s qualifications to sit on our Board include his extensive executive and business leadership experience with companies, investment firms and government, combined with his dedication and commitment to public interest through corporate social impact and civil rights.